To the full analysis
Buyback calculator for Dyne Therapeutics
Dyne Therapeutics stock: key metrics
DYNDyne Therapeutics had an operating margin of 0% and a return on invested capital (ROIC) of −41.2% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2007 | 35.1% | 19.5% | 8.5% |
| 2008 | 47.8% | 20.0% | 4.9% |
| 2009 | 51.6% | −33.8% | −51.1% |
| 2010 | 49.2% | −0.5% | −10.1% |
| 2011 | 39.2% | −14.9% | −103.8% |
| 2012 | −8,833.3% | 23,800.0% | 2,900.0% |
| 2013 | −38,066.7% | −10,600.0% | −11,866.7% |
| 2014 | 21.9% | −21.7% | −4.6% |
| 2015 | −140.9% | 7.6% | 5.9% |
| 2016 | −67.0% | −46.9% | −90.8% |
| 2017 | −479.4% | −81.4% | 15.0% |
| 2018 | no data | no data | no data |
| 2019 | no data | no data | no data |
| 2020 | no data | no data | no data |
| 2021 | no data | no data | no data |
| 2022 | no data | no data | no data |
| 2023 | no data | no data | no data |
| 2024 | no data | no data | no data |
| 2025 | no data | no data | no data |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2007 | 5.9% | 14.5% | 2.0% |
| 2008 | 3.9% | 17.6% | 1.2% |
| 2009 | −43.5% | −16.8% | −11.5% |
| 2010 | −8.5% | −0.2% | −2.3% |
| 2011 | −100.0% | −4.6% | −39.9% |
| 2012 | 3.5% | 29.8% | 1.9% |
| 2013 | −16.1% | −7.3% | −6.7% |
| 2014 | −2.2% | −4.4% | −0.6% |
| 2015 | 1.7% | 0.6% | 0.4% |
| 2016 | −60.7% | −5.4% | −9.5% |
| 2017 | 4.0% | −3.4% | 0.6% |
| 2018 | 98.6% | −0.1% | −58.2% |
| 2019 | −96.4% | no data | −82.4% |
| 2020 | −17.2% | −26.0% | −16.6% |
| 2021 | −40.5% | −32.1% | −35.1% |
| 2022 | −66.6% | −40.0% | −54.9% |
| 2023 | −100.0% | −97.6% | −100.0% |
| 2024 | −50.4% | −70.8% | −45.9% |
| 2025 | −45.9% | −41.2% | −37.6% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.